Virus replicon particles expressing porcine reproductive and respiratory syndrome virus proteins elicit immune priming but do not confer protection from viremia in pigs by unknown
Eck et al. Vet Res  (2016) 47:33 
DOI 10.1186/s13567-016-0318-0
RESEARCH ARTICLE
Virus replicon particles expressing 
porcine reproductive and respiratory syndrome 
virus proteins elicit immune priming but do not 
confer protection from viremia in pigs
Melanie Eck1,2, Margarita García Durán3, Meret E. Ricklin1, Samira Locher1, Javier Sarraseca3, 
María José Rodríguez3, Kenneth C. McCullough1, Artur Summerfield1,4, Gert Zimmer1 and Nicolas Ruggli1*
Abstract 
Porcine reproductive and respiratory syndrome virus (PRRSV) is the causative agent of one of the most devastating 
and economically significant viral disease of pigs worldwide. The vaccines currently available on the market elicit only 
limited protection. Recombinant vesicular stomatitis virus (VSV) replicon particles (VRP) have been used successfully 
to induce protection against influenza A virus (IAV) in chickens and bluetongue virus in sheep. In this study, VSV VRP 
expressing the PRRSV envelope proteins GP5, M, GP4, GP3, GP2 and the nucleocapsid protein N, individually or in 
combination, were generated and evaluated as a potential vector vaccine against PRRSV infection. High level expres-
sion of the recombinant PRRSV proteins was demonstrated in cell culture. However, none of the PRRSV antigens 
expressed from VRP, with the exception of the N protein, did induce any detectable antibody response in pigs before 
challenge infection with PRRSV. After challenge however, the antibody responses against GP5, GP4 and GP3 appeared 
in average 2 weeks earlier than in pigs vaccinated with the empty control VRP. No reduction of viremia was observed 
in the vaccinated group compared with the control group. When pigs were co-vaccinated with VRP expressing IAV 
antigens and VRP expressing PRRSV glycoproteins, only antibody responses to the IAV antigens were detectable. 
These data show that the VSV replicon vector can induce immune responses to heterologous proteins in pigs, but 
that the PRRSV envelope proteins expressed from VSV VRP are poorly immunogenic. Nevertheless, they prime the 
immune system for significantly earlier B-cell responses following PRRSV challenge infection.
© 2016 Eck et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Infections with porcine reproductive and respiratory 
syndrome virus (PRRSV) causes reproductive fail-
ures in sows [1] and respiratory disorders particularly 
in young pigs [2], which results in important economic 
losses worldwide [3, 4]. Recently, highly pathogenic 
PRRSV strains have emerged in China [5] and Eastern 
Europe [6]. PRRSV is an enveloped positive sense single-
stranded RNA virus belonging to the family Arteriviridae 
within the order Nidovirales [7]. Two PRRSV genotypes 
can be distinguished, type 1 PRRSV of European origin 
and type 2 PRRSV originating from North America and 
China, both spreading worldwide with high genetic and 
antigenic diversity [8, 9]. The PRRSV genome consists 
of at least 10 open reading frames (ORF). ORF 1a and 
1b encode the non-structural proteins from two poly-
proteins pp1a and pp1ab that are further processed pro-
teolytically, as well as two proteins nsp2TF and nsp2N 
resulting from ribosomal frameshifts within the nsp2 
gene (for a detailed review see [10]). The remaining ORFs 
encode the structural proteins on subgenomic messen-
ger RNAs. ORF 2a, 2b and 3–7, encode the glycoprotein 
2 (GP2) also termed GP2a, the non-glycosylated protein 
2b also termed E, the glycoproteins GP3, GP4, GP5, the 
non-glycosylated membrane protein M (from ORF6) and 
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the nucleocapsid protein N (from ORF7), respectively 
(reviewed in [11]). Recently, an alternative ORF5a pro-
tein was identified as a minor component of the equine 
arteritis virus (EAV) [12] and the PRRSV virions [13]. 
GP5 and M form a disulphide-linked heterodimer that 
is essential for the formation of infectious particles [14, 
15]. For EAV, the glycoproteins GP2, GP3 and GP4 form 
a heterotrimeric complex that is stabilised by disulphide 
bonds, which has not been demonstrated for PRRSV yet 
(reviewed in [11]). The PRRSV GP5–M and GP2–GP3–
GP4 complexes are linked essentially through non-cova-
lent interactions between GP5 and GP4 [16]. The basic 
protein N associates with the viral RNA genome to form 
the nucleocapsid. N is the most immunogenic PRRSV 
structural protein. It elicits a strong antibody response 
a few days post infection (pi). These antibodies do how-
ever not neutralize the virus and are therefore not pro-
tective [17]. The major neutralizing epitopes are found on 
GP5 [18–21] and GP4 [22–24] which are also the most 
diverse structural proteins between isolates [25]. Neu-
tralizing epitopes were also found on M, GP3 and GP2 
[26–28], but their contribution to protection is unclear. 
GP5 co-expressed with M elicits a better neutralizing Ab 
response than GP5 alone [29, 30]. However, neutralizing 
antibodies appear typically several weeks only after the 
onset of the first antibody response, simultaneously with 
clearance of the virus from the bloodstream [21, 31].
The development of vaccines against PRRSV has been 
only partially successful so far and remains a challeng-
ing task (for comprehensive reviews, see [32–34]). There 
are currently two types of PRRSV vaccines on the mar-
ket: modified live-virus vaccines (MLV) and inactivated 
vaccines [35–37]. MLV are typically more efficacious 
than inactivated vaccines [38, 39]. Numerous alterna-
tive PRRSV vaccine approaches have been explored with 
limited success so far (reviewed in [32, 40]). These efforts 
include for instance DNA vaccines, subunit and peptide 
vaccines, viral vector vaccines and plant-derived vaccines 
[30, 41–46].
Propagation-incompetent recombinant vesicular sto-
matitis virus (VSV) represents yet another vector vac-
cine approach. Recombinant VSV replicons lacking the 
VSV glycoprotein (G) gene and carrying genes of inter-
est instead can be packaged in virus replicon particles 
(VRP) with high infectious titres using a complementing 
G-expressing cell line [47]. Such VRP were used success-
fully in the past to induce protection against SARS coro-
navirus in a mouse model [48], influenza A virus (IAV) in 
chickens and mice [49–51], and bluetongue virus (BTV) 
in sheep [52]. VSV VRP are safe due to the lack of gly-
coprotein G expression, preventing assembly and spread 
of virus particles. Pigs have typically no pre-existing 
immunity against VSV. Thus, VSV replicons represent 
an attractive novel vaccine platform for pigs. They have 
however not been evaluated in pigs yet. In the present 
study, VSV VRP were generated to express different com-
binations of the major and minor PRRSV glycoproteins. 
The immunogenicity and protective potential of these 
VRP were assessed in pigs.
Materials and methods
Cells and virus
MARC-145 cells (ATCC, LGC Standards) were grown in 
Dulbecco’s modified Eagle medium (DMEM; Life Tech-
nologies) supplemented with 10% foetal bovine serum 
(FBS; Biowest). BHK-21 cells were obtained from the 
German Cell Culture Collection (DSZM) and grown 
in Earle’s minimal essential medium Eagle (MEM; Life 
Technologies) supplemented with 5% FBS. BHK-G43, a 
transgenic BHK-21 cell clone expressing the VSV G pro-
tein in a regulated manner, were maintained as described 
previously [47]. The type 1 PRRSV strain Olot/91 was 
kindly provided by Luis Enjuanes (Centro Nacional de 
Biotecnología, Madrid, Spain). This virus was a MARC-
145-adapted variant of the original Olot/91 virus and was 
therefore propagated and titrated in MARC-145 cells.
Antibodies
For the detection of PRRSV proteins, monoclonal anti-
body (mAb) 13E2 directed against PRRSV N, and mAb 
VII2D directed against amino acids 73–84 of PRRSV 
GP3 were kindly provided by Hans Nauwynck (Univer-
sity Ghent, Belgium). A polyclonal rabbit serum against 
PRRSV GP4 was obtained from Luis Enjuanes (Centro 
Nacional de Biotecnología, Madrid, Spain). This serum 
was generated at BioGenes (Germany) with purified 
recombinant GP4 from PRRSV Olot/91 expressed with 
the baculovirus system. The mAb 11E10C7 directed 
against PRRSV M, and the mAb 3AH9 against PRRSV 
GP5 were a gift from INGENASA (Madrid, Spain). The 
rabbit anti-Myc antiserum C3956, the mouse anti-Flag 
M2 antibody and the anti-α-tubulin mAb were pur-
chased from Sigma-Aldrich. The mouse anti-HA anti-
body 12CA5 was from Roche. The secondary antibodies 
goat anti-mouse IgG Alexa 546 and goat anti-rabbit IgG 
Alexa 546 were from Molecular Probes. The anti-swine 
IgG antibody conjugated with rhodamine was purchased 
from Rockland. The polyclonal rabbit anti-mouse IgG 
coupled with horseradish peroxidase was from DAKO.
Construction of recombinant VSV replicon particles
The cDNA of GP5 and M and the codon-optimized 
cDNA of GP2, GP3 and GP4 from the PRRSV Olot/91 
strain (GenBank Accession Number KC862570) were 
derived from pSL-ORF5–ORF6 and pSL-GP3–2–4, 
respectively, kindly provided by Luis Enjuanes (Centro 
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Nacional de Biotecnología, Madrid, Spain). The codon-
optimized cDNA of N from the Olot/91 strain (GenBank 
Accession Number AGW23409) was synthesized by 
GenScript (Piscataway). For generation of recombinant 
VSV replicons, GP5 or N were inserted into the plasmid 
pVSV* using MluI and BstEII restriction sites upstream 
and downstream of the fourth transcription unit, replac-
ing the G gene of VSV in analogy to a previous report 
[49]. This replicon contained an additional transcrip-
tion unit at position 5, expressing the green fluorescent 
protein (GFP) referred to by an asterisk (*) in the vec-
tor nomenclature. The resulting plasmids were desig-
nated pVSV*ΔG(GP5) and pVSV*ΔG(N), respectively. 
For generation of a dual antigen expression vector, the 
M cDNA was inserted into pVSV*ΔG(GP5) using XhoI 
and NheI restriction sites, thereby replacing the GFP 
gene in the fifth transcription unit. The resulting plas-
mid was designated pVSVΔG(GP5/M). For generation 
of a triple antigen expression vector, the cDNA of GP4, 
GP3 and GP2 was inserted into a VSVΔG vector contain-
ing 7 transcription units described recently [53] using the 
MluI (in case of GP4), XhoI (in case of GP3) and NheI 
(in case of GP2) restriction sites. The resulting plasmid 
was designated pVSVΔG(GP4/GP3/GP2). For expres-
sion of a modified M and GP3 containing a short peptide 
epitope at the C terminus, the M and GP3 gene, respec-
tively, were inserted without stop codon into the pCMV-
3Tag-3A plasmid vector (Agilent Technologies) upstream 
and in frame with a triple Flag epitope (DYKDDDDK)-
coding region followed by a stop codon. The M-Flag 
and GP3-Flag open reading frames were amplified by 
PCR and inserted into the fourth transcription unit 
of pVSV*ΔG, resulting in the plasmids pVSV*ΔG(M-
Flag) and pVSV*ΔG(GP3-Flag), respectively. The anti-
gens GP5 and GP4 were modified by fusing a short HA 
epitope (YPYDVPDYA) to the C terminus, while GP2 
was modified at the C terminus with a short Myc epitope 
(EQKLISEEDL). The ORFs were inserted into the fourth 
transcription unit of pVSV*ΔG resulting in the plas-
mids pVSV*ΔG(GP5-HA), pVSV*ΔG(GP4-HA), and 
pVSV*ΔG(GP2-Myc), respectively. For expression of 
the GP3 ectodomain (GP3ecto) without the C-terminal 
transmembrane domain, a gene cassette encoding the 
amino acids 29–176 of GP3 (numbering according to 
GenBank Accession Number AGW23404) was inserted 
in frame with the Igκ leader sequence and an optimal sig-
nalase cleavage site in the mammalian expression vector 
pSecTag-2A (Invitrogen). In this way GP3ecto was fused 
to a Myc peptide epitope and a histidine tag (6xHis) at the 
C terminus, followed by a stop codon. This Igκ-GP3ecto-
Myc-6xHis construct was then amplified by PCR and 
inserted into the fourth transcription unit of pVSV*ΔG, 
resulting in the plasmid pVSV*ΔG(GP3ecto-Myc). For 
expression of IAV proteins, the cDNA encoding HA, NA, 
NP and M2 of IAV A/swine/Belzig/2/01 (H1N1) were 
kindly provided by Jürgen and Olga Stech (Friedrich-
Loeffler-Institut, Greifswald-Insel Riems, Germany). The 
genes were inserted into the plasmid pVSV* using the 
MluI and BstEII restriction sites, replacing the G gene 
of VSV as described [49]. All nucleotide sequences were 
confirmed by Sanger sequencing. The recombinant rep-
licons were propagated in the BHK-G43 helper cell line 
providing the VSV G protein in trans, yielding infec-
tious VRP with titres of 107–108 infectious units (IU)/
mL as described previously [54]. For the titrations, GFP 
expression was used as readout. For the detection of VRP 
that did not express GFP, infected cells were fixed with 
PBS containing 3% paraformaldehyde (PFA) for 20 min, 
washed with PBS containing 0.1 M (w/v) glycine and then 
permeabilized with 0.25% (v/v) Triton X-100. The cells 
were incubated with a rabbit anti-VSV serum and sub-
sequently with a goat anti-rabbit horseradish peroxidase 
conjugate (DAKO) and stained with 3-amino-9-ethylcar-
bazole (AEC)/H2O2 as substrate. An overview of all con-
structed VSV VRP is provided in Table 1.
Immunofluorescence
MARC-145 cells grown on 12-mm-diameter cover slips 
were inoculated for 90  min at 37  °C with recombinant 
VRP using a multiplicity of infection (MOI) of 3 IU/cell. 
At 6  h post infection, the cells were fixed with 3% PFA 
for 20 min and washed with PBS containing 0.1 M (w/v) 
glycine. The cells were permeabilized with 0.25% (v/v) 
Triton X-100 for 5–10  min and subsequently incubated 
with primary and secondary antibodies, diluted in PBS 
containing 1% bovine serum albumin (BSA). After each 
incubation period (60 min, room temperature), the cells 
were washed three times with PBS. Finally, the cells were 
washed with distilled water and embedded in Mowiol 
4-88 mounting medium (Sigma-Aldrich).
Table 1 VSV VRP expressing PRRSV structural proteins.
a The * indicates the presence of the GFP gene in the vector.









GP4, GP3, GP2 VSVΔG(GP4/GP3/GP2)
N VSV*ΔG(N)
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Western blot
Confluent MARC-145 cells in 6-well tissue culture plates 
were inoculated for 90  min at 37  °C with the VRP and 
further incubated for 6–8 h. The cells were then washed 
with cold PBS and lysed with Nonidet-P40 buffer (50 mM 
Tris, pH 7.5, 150  mM NaCl, 1% NP-40) supplemented 
with protease inhibitor cocktail (Sigma-Aldrich). Pro-
teins were dissolved in sodium dodecyl sulphate (SDS) 
sample buffer (125  mM Tris-HCl, pH 6.8, 20% glycerol, 
1% bromophenol blue, 4% SDS) with or without 5% (v/v) 
β-mercaptoethanol (βME), separated (2 µg protein/lane) 
by SDS 12% polyacrylamide gel electrophoresis (PAGE), 
and transferred to nitrocellulose membranes by semi-dry 
blotting according to standard protocols. The nitrocel-
lulose membranes were blocked overnight at 4  °C with 
Odyssey Blocking Reagent (LI-COR Biosciences) diluted 
1:2 with PBS. For immunodetection, the membranes 
were incubated with primary and IRDye-conjugated sec-
ondary antibodies, diluted in Odyssey Blocking Reagent/
PBS (1:2). After each incubation period (60  min, room 
temperature), the membranes were washed with PBS 
supplemented with 0.1% Tween-20. Finally, the mem-
branes were washed twice in detergent-free PBS and 
images acquired with the Odyssey Infrared Imaging Sys-
tem (LI-COR Biosciences).
Experimental design of animal studies
All pigs were obtained from the specific pathogen free 
(SPF) breeding facility of the Institute of Virology and 
Immunology IVI. Three experiments were performed. 
For each experiment the pigs were randomly assigned to 
treatment groups housed in separate stables. The groups 
were immunized by intramuscular injection of 5  mL 
of cell culture supernatant containing 107–108  IU/mL 
recombinant VRP. In the first experiment, 2 groups of 
pigs (n = 5) were immunized three times at 9½, 13½ and 
18½ weeks of age with VSVΔG(GP5/M) or with the con-
trol VSV*ΔG VRP, respectively. In the second experiment, 
one group of pigs (n =  4) was immunized twice at 10½ 
and 14½ weeks of age with a mixture of VSVΔG(GP5/M) 
and VSVΔG(GP4/GP3/GP2) and the second group 
(n  =  3) received the control VSV*ΔG VRP. In the third 
experiment, 4 groups of pigs (n  =  2) were immunized 
three times at 5, 6 and 7  months of age with two differ-
ent VSV VRP each injected at two different sites, i.e. 
VSV*ΔG(N) and VSV*ΔG(HABelz), VSV*ΔG(GP3ecto-
Myc) and VSV*ΔG(M2Belz), VSV*ΔG(GP4-HA) and 
VSV*ΔG(NABelz), VSV*ΔG(control) and VSV*ΔG(NPBelz), 
respectively. In all experiments, the pigs were challenged 
via the intranasal route with 106 TCID50/animal of the 
PRRSV strain Olot/91 3–4 weeks after the last vaccination. 
The challenge virus was diluted in 5 mL MEM and admin-
istered dropwise intranasally. Blood was taken before each 
vaccination and at regular intervals after vaccination and 
after the challenge infection. Serum was stored at −70 °C. 
Body temperature and clinical score were monitored daily 
according to a defined scoring system [55].
Ethics statement
The experiments in pigs were performed in compliance 
with the Swiss animal protection law and approved by the 
animal welfare committee of the canton of Berne, Swit-
zerland (Authorization Number BE89/11).
PRRSV titration
Titration by end point dilution was performed in MARC-
145 cells grown in 96-well plates. The cells were inocu-
lated with tenfold serially diluted serum samples. At 48 h 
pi, the cells were fixed and immunoperoxidase stain-
ing with the anti-N mAb 13E2 was performed accord-
ing to standard protocols. The 50% end point titre was 
expressed as tissue culture infectious dose 50% (TCID50)/
mL, with a limit of detection of 1.7 log10 TCID50/mL.
RNA extraction and quantitative RT‑PCR (RT‑qPCR)
Total cellular RNA was extracted from pig sera using the 
NucleoSpin Multi 96 Virus kit (Macherey–Nagel) on a 
Freedom EVO Robot (Tecan) and stored at −70  °C. For 
detection of viral RNA, a reverse transcriptase quantita-
tive PCR (RT-qPCR) based on the amplification of the 
conserved region of ORF7 was performed in duplicates 
employing GFP messenger RNA as internal control [56]. 
The results were expressed as the total number of cycles 
minus the quantification cycle (Cq)-value.
Enzyme‑linked immunosorbent assay (ELISA)
The ELISA PRRS X3 (IDEXX Laboratories) was used 
for measuring anti-PRRSV IgG antibodies. Samples to 
positive (S/P) ratios higher than 0.4 were considered 
positive. Antibodies against PRRSV GP5, GP4 and GP3 
were detected using in house competitive (GP5) and 
indirect (GP4 and GP3) ELISAs (INGENASA, Madrid, 
Spain). These ELISAs were performed with plates 
coated with recombinant GP5, GP4 and GP3 antigens 
from PRRSV Olot/91. For the GP5 ELISA, the percent-
age of competition was calculated using the formula 
[(ODneg − ODsample)/(ODneg − ODpos)] × 100. Posi-
tive and negative controls were provided by INGENASA 
(Spain). Samples were considered positive if the percent-
age of competition was >37%. For the indirect ELISAs, 
appropriate cut-offs were set. For the detection of C-reac-
tive protein (CRP; Genway), haptoglobin (Hp; Genway) 
and IFN-γ (Mabtech) in pig sera, commercially available 
ELISAs were used according to the manufacturer’s pro-
tocols. Porcine interferon-α (IFN-α) was determined by 
ELISA as described previously [57].
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Virus neutralization assay
Serum samples were heat inactivated at 56 °C for 30 min 
prior to performing the serum neutralization assay. 50 µL 
of two-fold serially diluted sera were mixed with an equal 
volume of 100 TCID50 of PRRSV Olot/91 and incubated 
in 96-well tissue culture plates for 1  h at 37  °C. After 
1 h, 104 MARC-145 cells were added to each well. After 
6 days, the culture plate was fixed with 3% PFA. The pres-
ence of virus was detected by CPE and by staining with 
the anti-N mAb and AEC/H2O2. The virus neutralization 
titre was expressed as the reciprocal of the serum dilu-
tion leading to 50% reduction of infection.
Statistical analysis
Data were analysed with the GraphPad Prism 6.01 soft-
ware. Significant differences between groups were 
assessed by multiple t tests. P  <  0.05 was considered 
significant.
Results
Expression of PRRSV structural proteins using VSV VRP
In previous work, a propagation-incompetent VSV rep-
licon vector was generated by replacing the gene of the 
glycoprotein G in the fourth transcription unit of the 
viral genome with influenza virus genes. This replicon 
contained the GFP gene [referred to by an asterisk (*) in 
the vector nomenclature] in an additional transcription 
unit at position 5 [49]. Based on this vector, we gener-
ated several VSV VRP expressing the individual struc-
tural antigens of PRRSV Olot/91 or combinations thereof 
for evaluation as PRRS vaccine candidates (see “Materi-
als and methods”; Table 1). The empty parental VSV*ΔG 
vector served as control [49].
The VSV VRP-mediated expression of the recombi-
nant PRRSV antigens was studied in MARC-145 cells, 
taking advantage of the broad tropism of the VSV par-
ticles. This allowed direct comparison of the recombi-
nant proteins with the viral proteins in PRRSV-infected 
MARC-145 cells. GP5 was detected by immunofluo-
rescence with the anti-GP5 mAb in cells infected with 
either VSV(GP5-HA) or VSV(GP5/M), but not in cells 
infected with the parental VSV*ΔG (Figure  1A). The 
anti-M mAb reacted specifically with cells infected 
with VSV*ΔG(M-Flag) or with VSVΔG(GP5/M). In 
Western blots, porcine anti-PRRSV serum reacted 
with 24 and 18  kDa proteins from VSVΔ(GP5/M)-
infected cells, representing GP5 and M, respectively 
(Figure  1B). PRRSV Olot/91-infected cells served as 
positive control showing expression of GP5, M and N. 
Under non-reducing conditions, porcine anti-PRRSV 
serum revealed a protein of higher molecular weight, 
indicating disulphide-linked association of GP5 and M 
(not shown). Expression of GP5 and M of the expected 
molecular weight was confirmed in Western blots 
with the anti-GP5 and anti-M mAbs, respectively 
(Figure 1B). VSV*ΔG-infected cells were used as a nega-
tive control and did not show any expression of PRRSV 
proteins. These results show that the PRRSV GP5 and 
M antigens could be successfully co-expressed from a 













































































Figure 1 Characterization of VRP-mediated expression of GP5 
and M. A Immunofluorescence analysis of MARC-145 cells 6 h after 
infection with VSV*ΔG(GP5-HA), VSV*ΔG(M-Flag), VSVΔG(GP5/M) or 
with the VSV*ΔG control VRP. In the top panels, expression of GP5 
is detected using the anti-GP5 mAb 3AH9. In the bottom panels, 
expression of M is detected using the anti-M mAb 11E10C7. B West-
ern blot analysis of lysates from non-infected cells (lane 1) or cells 
infected with VSV*ΔG (lane 2), VSVΔG(GP5/M) (lane 3), PRRSV Olot/91 
(lane 4) or mock (lane 5). The proteins were separated by SDS-PAGE 
under reducing (+βME) conditions and blotted onto a nitrocellulose 
membrane. The GP5 and M proteins were detected with the anti-GP5 
and anti-M mAbs and with a porcine anti-PRRSV serum that reacted 
also with N. α-tubulin served as loading control using the anti-α-
tubulin mAb. Protein molecular weight (kDa) standards are indicated.
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MARC-145 cells infected with either VSV*ΔG(GP3-
Flag) or VSVΔG(GP4/GP3/GP2) reacted specifically 
with the anti-GP3 mAb, while cells infected with either 
VSV*ΔG(GP4-HA) or VSVΔG(GP4/GP3/GP2) reacted 
with a polyclonal anti-GP4 immune serum (Figure  2). 
Since a specific antibody against GP2 was not available, 
the expression of GP2 could not be demonstrated. Any 
tag was omitted on purpose in the VSVΔG(GP4/GP3/
GP2) to preserve the natural conformation of the three 
proteins. Nevertheless, Myc-tagged GP2 expression was 
detected from VSV*Δ(GP2-Myc) using the anti-Myc 
serum (not shown).
With the aim of evaluating whether protein secretion 
into the supernatant may enhance B-cell responses, the 
VSV*ΔG(GP3ecto-Myc) replicon was constructed for the 
expression of the ectodomain of GP3 fused to a Igκ leader 
sequence and an optimal signalase cleavage site. The 
Myc-tagged ectodomain of GP3 reacted with the anti-
GP3 mAb and anti-Myc serum as expected (Figure 3A). 
Western-blot analysis with the anti-Myc serum demon-
strated the presence of a 35 kDa protein in the cell lysate 
(ly) which was however missing in the supernatant (sn) 
of VSV*ΔG(GP3ecto-Myc) infected MARC-145 cells 
(Figure  3B). This showed that the ectodomain of GP3 
was retained in intracellular compartments despite the 
Igκ signal sequence and the lack of the transmembrane 
domain.
Finally, expression of the PRRSV N antigen by 
VSV*ΔG(N) was demonstrated by immunofluorescence 
(Figure  4A) and by Western blot (Figure  4B) using the 
anti-N mAb. A 16 kDa protein was detected in the lysate 
of both, VSV*ΔG(N)- and PRRSV Olot/91-infected cells.
Immunization of pigs with VSV VRP co‑expressing GP5 
and M primes the pigs for earlier antibody responses 
against challenge virus infection but does not protect 
from viremia
The GP5 and M complex constitutes the major protein 
component of the PRRSV envelope against which neu-
tralizing antibodies are formed [18, 19, 26]. Therefore, 
we first determined the immunogenicity of GP5/M-
recombinant VSV replicons in pigs. Two groups of five 
pigs were immunized three times with VSVΔG(GP5/M) 
or with the control VSV*ΔG respectively, and were 
challenged 3  weeks later with the homologous PRRSV 
Olot/91 strain.
Following PRRSV challenge infection, three 


















Figure 2 Characterization of VRP-mediated expression of GP3 
and GP4. Immunofluorescence analysis of MARC-145 cells 6 h after 
infection with VSV*ΔG(GP3-Flag), VSV*ΔG(GP4-HA), VSVΔG(GP4/GP3/
GP2) or with the VSV*ΔG control VRP. Expression of GP3 (top panels) 
and GP4 (bottom panels) were detected with the anti-GP3 mAb VII2D 














































Figure 3 Characterization of VRP-mediated expression of the 
GP3 ectodomain. A Immunofluorescence analysis of MARC-145 
cells 6 h after infection with VSV*ΔG(GP3ecto-Myc) or with the 
VSV*ΔG control. Expression of GP3ecto is detected with a rabbit 
anti-Myc serum (top panels) and with the anti-GP3 mAb VII2D (bot-
tom panels). B Western blot analysis of lysates (ly) and supernatants 
(sn) from cells infected with VSV*ΔG(GP3ecto-Myc) separated by 
SDS-PAGE under non-reducing (-βME) conditions, using the anti-Myc 
serum for GP3ecto-Myc detection (arrowhead). Protein molecular 
weight (kDa) standards are indicated.
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fever (40.3–41.5 °C) on day 2 pi, whereas the control pigs 
had no fever despite slightly elevated body temperature 
(Figures 5A and B). All animals developed a low viremia 
of short duration (Figures 5C and D). A maximum mean 
virus titre of 3.0 log10 TCID50/mL was reached in the 
serum at day 2 post challenge. The virus was detectable 
up to day 8 and viral RNA up to day 13 after challenge. 
No significant differences in viremia and viral RNA in 
serum were observed between the vaccinated group and 
the control group at any time.
Before challenge infection, vaccination with 
VSVΔG(GP5/M) did not induce any detectable antibody 
response against GP5 as measured by ELISA (not shown). 
The first GP5-specific antibody responses were detected 
by ELISA in the VSVΔG(GP5/M)-vaccinated group in 2 
out of five pigs on day 6 after the challenge, and all pigs 
of this group were positive on day 13 pi. All pigs of the 
VSV*ΔG control group remained GP5 antibody negative 
at this time (Table 2). In the VSV*ΔG control group, GP5-
specific antibodies were detected for the first time on day 
21 pi in 2 out of the 5 pigs. Seroconversion against N in 
response to the PRRSV challenge infection was similar 
in the two groups, with the first N-specific seroconver-
sion observed on day 10 pi (Table 2). Virus neutralizing 
antibodies were not detected in any of the animals, nei-
ther before nor after the challenge (day 0 and day 21 pi). 
IFN-α and IFN-γ could not be detected in the serum at 
any time (data not shown). Specific T-cell responses were 
not detected before challenge (not shown) and were 
therefore not further investigated. The acute phase pro-
teins CRP and Hp which are early and sensitive markers 
of disease and inflammation including PRRSV infection 
[58] were increased in both groups between days 2 and 6 
pi (Figures 5E and F). However, no significant differences 
could be detected between vaccinated and control ani-
mals at any time. Thus, apart from priming pigs for GP5-
specific antibody responses after challenge infection, the 
VSVΔG(GP5/M) vector could not induce any serocon-
version against GP5 before challenge nor any sign of pro-
tection from viremia after infection.
Immunization of pigs by co‑expression of GP5, M, GP4, 
GP3 and GP2 from two VSV VRP does not further enhance 
antibody responses nor protect against challenge virus 
infection
In order to determine whether the immune responses 
could be enhanced and induced before challenge by 
providing the three minor glycoproteins GP4, GP3 and 
GP2 together with GP5 and M, pigs (n = 4) were immu-
nized twice with a mixture of VSVΔG(GP5/M) and 
VSVΔG(GP4/GP3/GP2) or with VSV*ΔG as control 
(n = 3) followed by PRRSV Olot/91 challenge.
On day 2 after challenge, two out of the four vac-
cinated pigs developed mild fever (40  °C; Figure  6A) 
while all control animals remained free of fever (<40 °C; 
Figure 6B). All animals developed a short viremia follow-
ing challenge infection with no significant differences in 
viral RNA load and virus titres between the vaccinated 
and control groups (Figures  6C  and D). As in the pre-
vious experiment, a maximum mean virus titre of 3.0 
log10TCID50/mL was reached at day 2 post challenge.
Again, before challenge infection, vaccination with 
VRP expressing the structural proteins of PRRSV did 
not induce any detectable antibody response against 
GP5, GP4 and GP3 as measured by ELISA (not shown). 
Following challenge infection, GP5-specific antibody 
responses were detected on day 7 pi in 2 out of 4 pigs, and 
all pigs vaccinated with VRP expressing the PRRSV pro-
teins seroconverted to GP5 at day 11 pi (Table 3). All pigs 
of the VSV*ΔG control group remained negative until 
day 24 pi. Seroconversion to GP3 (Table 3) was detected 
as early as day 7 pi in 3 of 4 pigs of the vaccinated group 



























Figure 4 Characterization of VRP-mediated expression of N. 
A Immunofluorescence analysis of MARC-145 cells 6 h after infection 
with VSV*ΔG(N) or with the VSV*ΔG control. The expression of N is 
detected with the anti-N mAb 13E2. B Western blot analysis of lysates 
from non-infected cells (lane 1) or cells infected with VSV*ΔG (lane 
2), VSVΔ*G(N) (lane 3), PRRSV Olot/91 (lane 4) or mock (lane 5). The 
proteins were separated by SDS-PAGE under non-reducing (-βME) 
conditions and blotted onto a nitrocellulose membrane. N antigen 
was detected with the anti-N mAb as above. Protein molecular 
weight (kDa) standards are indicated.
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VSV*ΔG control group remained negative until day 24 pi. 
A GP4-specific immune response could be detected only 
in 2 out of 4 vaccinated animals on day 24 pi. Here also, 
the seroconversion against N following challenge was 
similar in the two groups (Table 3). None of the animals 
developed any neutralizing antibodies before nor after 











































































































Figure 5 Body temperatures, virus load and acute phase proteins after challenge infection of pigs vaccinated with VSVΔG(GP5/M) 
or with VSV*ΔG as control. Two groups of 5 SPF pigs each were vaccinated three times with 28 and 35 days interval, with 107 PFU/pig of 
VSVΔG(GP5/M) or of VSV*ΔG as mock control, respectively. 4 weeks after the 3rd vaccination, the pigs were infected intranasally with 106 PFU/pig 
of the homologous Olot/91 virus. The body temperatures A, B are shown for the individual animals. Blood was collected at the indicated days after 
infection. PRRSV load in serum was determined by real-time RT-qPCR (C) and by virus titration in MARC-145 cells (D), and the values expressed in 
45-Cq and TCID50/mL serum (detection limit 1.7 log10 TCID50/mL), respectively. The serum concentrations (µg/mL) of the porcine acute phase pro-
teins CRP (E) and Hp (F) were determined by ELISA. The data of panels C–F represent the mean of five pigs per group, with error bars representing 
the standard deviation (SD).
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challenge (day 0 and day 24 pi). IFN-α and IFN-γ were 
not found in any of the sera in this experiment either 
(data not shown) whereas the serum CRP and Hp lev-
els increased significantly in both groups between days 
2 and 4 after challenge and declined subsequently. On 
day 4 pi, the CRP and Hp levels were significantly dif-
ferent between the vaccinated and the control group 
(Figures 6E and F), suggesting that the vaccinated group 
developed a slightly reduced inflammatory response after 
co-vaccination with VSVΔG(GP5/M) and VSVΔG(GP4/
GP3/GP2).
Together, these two vaccination trials show that 
VSV VRP cannot induce any detectable seroconver-
sion against PRRSV before challenge nor any protection 
against virus infection and viremia. Nevertheless, these 
vectors can clearly prime pigs for earlier PRRSV-specific 
antibody responses after challenge infection.
The PRRSV envelope proteins expressed from VRP are 
poorly immunogenic in pigs, as opposed to influenza A 
virus proteins and to the PRRSV nucleocapsid protein
The poor immunogenicity of VSV VRP expressing 
PRRSV envelope proteins contrasts with previous reports 
showing protection against IAV and BTV infections 
in chickens and sheep, respectively [49, 50, 52]. Thus, 
the lack of antibody induction after immunization of 
pigs with VRP expressing the five PRRSV envelope pro-
teins raises the questions whether this vector vaccine 
is suitable for induction of antibody responses in pigs 
or whether the PRRSV proteins are poorly immuno-
genic per se. In order to test this, the immunogenicity 
of PRRSV and IAV proteins expressed from VSV VRP 
was assessed in the same animal by co-vaccination with 
two different VSV VRP constructs expressing a PRRSV 
protein (N, GP3ecto, GP4 or empty vector) and a IAV 
protein (HA, M2, NA, NP), respectively, injected at two 
different sites (see “Materials and methods”). After 3 vac-
cinations, the pigs were challenged with the homologous 
PRRSV Olot/91 strain.
While, antibody responses were detected against all 
influenza virus proteins on day 14 after vaccination 
(including neutralizing antibodies, not shown), no sero-
conversion against any of the PRRSV proteins except N 
could be detected before challenge (Table  4). Pigs vac-
cinated with VSV*∆G(N) seroconverted on day 63 after 
vaccination (7  days after the third vaccination). Follow-
ing challenge infection with PRRSV Olot/91, the control 
group seroconverted on day 21 pi. There was no evidence 
of protection from virus infection after PRRSV chal-
lenge as indicated by the kinetics of viremia (data not 
shown). Nevertheless, a GP3-specific immune response 
was induced earlier after challenge (day 14 pi) in the 
VSV*ΔG(GP3ecto-Myc) vaccinated pigs compared with 
the VSV*ΔG-vaccinated pigs (no response on day 21 pi). 
A GP4-specific immune response was also induced on 
day 14 pi whereas the VSV*ΔG-vaccinated pigs stayed 
seronegative against GP4. In line with the two previous 
immunization trials, these data show again a priming 
effect. More importantly however, simultaneous vaccina-
tion of the same pigs with two different VRP show clearly 
that the PRRSV antigens are far less immunogenic than 
any of the IAV antigens tested.
Table 2 Seroconversion after vaccination of pigs with VSVΔG(GP5/M) followed by PRRSV challenge.
IDEXX X3 kit S/P ratios of >0.4 are considered positive. The mean values are indicated with the standard deviation.
a % Competition = (negative control mean [mean of optical absorbance] − sample mean)/(negative control mean − positive control mean) × 100. The mean values 
are indicated with the standard deviation.
b S/P ratio = (sample mean [mean of optical absorbance] − negative control mean)/(positive control mean − negative control mean).
Ab against  
PRRSV Ag  
(by ELISA)
Vaccine ELISA Days after PRRSV challenge infection
0 2 4 6 8 10 13 21
GP5 VSVΔG(GP5/M) Positive/total pigs 0/5 0/5 0/5 2/5 2/5 4/5 5/5 5/5
% Competitiona (positive pigs) 0 0 0 50 ± 12 49 ± 29 82 ± 15 82 ± 20 69 ± 15
Range for positive pigs 0 0 0 41–59 31–66 64–101 59–106 49–91
VSV*ΔG (control) Positive/total pigs 0/5 0/5 0/5 0/5 0/5 0/5 0/5 2/5
% Competition (positive pigs) 0 0 0 0 0 0 0 62 ± 13
Range for positive pigs 0 0 0 0 0 0 0 53–72
N VSVΔG(GP5/M) Positive/total pigs 0/5 0/5 0/5 0/5 0/5 2/5 4/5 4/5
S/P ratiob (positive pigs) 0 0 0 0 0 0.9 ± 0.4 1.0 ± 0.5 1.2 ± 0.1
Range (positive pigs) 0 0 0 0 0 0.5–1.2 0.6–1.7 1.1–1.3
VSV*ΔG (control) Positive/total pigs 0/5 0/5 0/5 0/5 0/5 0(1)/5 4/5 3/5
S/P ratio (positive pigs) 0 0 0 0 0 0 0.7 ± 0.2 1.4 ± 0.8
Range (positive pigs) 0 0 0 0 0 0 0.4–0.9 0.4–1.9
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Discussion
The current PRRSV vaccines on the market are of limited 
efficacy and come with several drawbacks [32]. Numer-
ous efforts have been invested and strategies proposed 
for the development of novel efficacious PRRSV vaccines 
based on the antigenic properties of the PRRSV struc-
tural proteins and on the immunobiology of the virus [32, 
34, 59]. Replicon vectors represent an elegant strategy to 
days post infection












































































































Figure 6 Body temperatures, virus load and acute phase proteins after challenge infection of pigs vaccinated with a mixture of 
VSVΔG(GP5/M) and VSVΔG(GP4/GP3/GP2) or with VSV*ΔG as control. Two groups of 4 and 3 SPF pigs were vaccinated two times at 28 days 
interval with a mixture of 107 PFU/pig of the VSVΔG(GP5/M) and VSVΔG(GP4/GP3/GP2) VRP or with the VSV*ΔG mock control, respectively. 26 days 
after the 2nd vaccination, the pigs were infected intranasally with 106 PFU/pig of the homologous Olot/91 virus. The body temperatures A, B 
are shown for the individual animals. Blood was collected at the indicated days post infection. PRRSV load in serum was determined by real-time 
RT-qPCR (C) and by virus titration in MARC-145 cells (D), and the values expressed in 45-Cq and TCID50/mL serum (detection limit 1.7 log10 TCID50/
mL), respectively. The serum concentrations (µg/mL) of the porcine acute phase proteins CRP (E) and Hp (F) were determined by ELISA. The data of 
panels C–F represent the mean of four and three pigs per group respectively, with error bars representing the SD and asterisks showing significant 
differences (p < 0.05).
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avoid the biological risks of virus spread and to circum-
vent potential immune modulating properties of modi-
fied live PRRSV vaccines [40]. Therefore, we explored the 
immunogenic and protective potential of VSV replicon 
particles as a vectored vaccine approach against PRRSV. 
Such VRP were successfully used before as efficacious 
experimental vaccines against SARS, IAV and BTV [48–
52]. In the present study, VSV replicons were engineered 
to express PRRSV structural proteins, individually or in 
combination (Table  1). Emphasis was on GP5, M, GP4 
and GP3, since these proteins are important targets for 
neutralizing and protective antibodies [11, 23, 26, 27], 
with the major neutralizing epitopes residing on GP5 
[18]. Since several studies have shown that co-expression 
of PRRSV antigens resulted in better humoral and cellu-
lar immune responses than expression of the individual 
proteins [30, 60], GP5, M, GP4, GP3 and GP2 proteins 
were co-expressed to partly mimic the formation of the 
GP5/M and GP4/3/2 oligomers.
Vaccination of pigs with VRP expressing two or five 
PRRSV envelope proteins in total did not result in any 
significant reduction of viremia compared with the 
control group. A tendency for reduced PRRSV-related 
inflammatory responses was observed only when all five 
proteins were expressed. Interestingly, vaccination with 
GP5/M induced fever up to 41.5  °C for 1  day following 
challenge infection with PRRSV Olot/91 whereas mock-
vaccinated pigs remained asymptomatic. Fever was less 
pronounced when all envelope proteins were included in 
the vaccine. Enhanced disease following vaccination with 
recombinant GP5 and M was observed previously [42, 
61]. This was attributed to antibody-dependent enhance-
ment of disease during natural infection, which is prob-
ably mediated by non-neutralizing antibodies [26, 62]. 
Such antibodies were shown to increase virus infection 
in porcine alveolar macrophage cultures and in vivo [62] 
involving different FcγR isoforms [63, 64].
Neutralizing antibodies were not found at any time 
following vaccination and challenge infection. Never-
theless, the vaccinated pigs seroconverted 15–17  days 
earlier than the mock-vaccinated animals after challenge 
virus infection, indicating that immunization with the 
recombinant VRP primed the immune system. In naïve 
pigs, the delayed seroconversion against the envelope 
proteins as opposed to the N protein after PRRSV infec-
tion or after immunization with vectored vaccines is well 
Table 3 Seroconversion after vaccination of pigs with VSVΔG(GP5/M) + VSVΔG(GP4/GP3/GP2) followed by PRRSV chal-
lenge.
a % Competition = (negative control mean [mean of optical absorbance] − sample mean)/(negative control mean − positive control mean) × 100. The mean values 
are indicated with the standard deviation.
b S/P ratio = (sample mean [mean of optical absorbance] − negative control mean)/(positive control mean − negative control mean). IDEXX X3 kit S/P ratios of >0.4 
are considered positive. The mean values are indicated with the standard deviation.
Ab against PRRSV 
Ag (by ELISA)
Vaccine ELISA Days after PRRSV challenge infection
0 2 4 7 9 11 14 24
GP5 VSVΔG(GP5/M) +  
VSVΔG (GP4/GP3/GP2)
Positive/total pigs 0/4 0/4 0/4 2/4 2/4 4/4 4/4 4/4
% Competitiona (positive 
pigs)
0 0 0 44 ± 0.6 48 ± 4 55 ± 10 89 ± 13 89 ± 11
Range (positive pigs) 0 0 0 43–44 45–51 45–65 72–102 77–100
VSV*ΔG (control) Positive/total pigs 0/3 0/3 0/3 0/3 0/3 0/3 0/3 1/3
% Competition (positive 
pigs)
0 0 0 0 0 0 0 42
Range (positive pigs) 0 0 0 0 0 0 0 42
GP3 VSVΔG(GP5/M) +  
VSVΔG (GP4/GP3/GP2)
Positive/total pigs 0/4 0/4 0/4 3/4 4/4 4/4 4/4 4/4
VSV*ΔG (control) Positive/total pigs 0/3 0/3 0/3 0/3 0/3 0/3 0/3 2/3
GP4 VSVΔG(GP5/M) +  
VSVΔG (GP4/GP3/GP2)
Positive/total pigs 0/4 0/4 0/4 0/4 0/4 0/4 1/4 2/4
VSV*ΔG (control) Positive/total pigs 0/3 0/3 0/3 0/3 0/3 0/3 0/3 1/3
N VSVΔG(GP5/M) +  
VSVΔG (GP4/GP3/GP2)
Positive/total pigs 0/4 0/4 0/4 0/4 0/4 0/4 1/4 4/4
S/P ratiob (positive pigs) 0 0 0 0 0 0 0.5 1.4 ± 0.4
Range (positive pigs) 0 0 0 0 0 0 0.5 0.9–1.9
VSV*ΔG (control) Positive/total pigs 0/3 0/3 0/3 0/3 1/3 1/3 1(1)/3 3/3
S/P ratio (positive pigs) 0 0 0 0 0.5 0.7 0.8 1.4 ± 0.7
Range (positive pigs) 0 0 0 0 0.5 0.7 0.8 0.8–2.1
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documented [31, 40, 42, 59]. Of note, with the MARC-
145-adapted Olot/91 virus used in this study, serocon-
version against N became detectable 9–14  days after 
challenge only (Tables 2, 3, 4) as opposed to the reported 
occurrence of anti-N antibodies as early as 5 to 7  days 
after PRRSV infection [31, 65]. This is probably related 
to the low level and short duration of replication of the 
MARC-145-adapted virus in pigs (Figures 5C, D, 6C, D). 
Despite the poor replication of this virus in vivo, vacci-
nation of pigs with VRP did not result in any significant 
reduction of viremia. A better immunogenicity of PRRSV 
proteins was reported when the antigens were modified, 
coupled to immunostimulatory molecules or adminis-
tered as purified proteins along with adjuvants [66, 67]. 
This raises the question whether the immunogenicity 
of the PRRSV envelope proteins expressed from VRP is 
affected by glycosylation, subcellular localization, intra-
cellular retention or low stability. In order to elaborate on 
this, GP3 was modified with the aim of obtaining secreted 
GP3 by replacing the leader sequence with a canoni-
cal Igκ signal sequence followed by an optimal signalase 
cleavage site and by deleting the hydrophobic transmem-
brane anchor. However, the modified GP3 was retained 
in the cell, and no seroconversion against GP3ecto was 
obtained in absence of challenge virus infection. The lack 
of GP3 secretion may be related to the fact that GP3 is 
naturally retained in intracellular compartments despite 
the N-terminal signal sequence [11].
In order to address the question whether PRRSV 
structural proteins are immunogenic at all when 
expressed by VSV VRP in pigs, a vector expressing 
PRRSV N protein was included in one vaccination 
trial. N was chosen because it is the most immuno-
genic structural protein after PRRSV infection [31, 
65]. Indeed, VSV*ΔG(N) was the only VRP capable of 
inducing a detectable antibody response in the absence 
of a viral challenge (Table 4). The co-vaccination experi-
ments with VRP expressing IAV and PRRSV envelope 
proteins corroborated these results. The IAV proteins 
were strongly immunogenic while the PRRSV envelope 
proteins were not, clearly demonstrating that the VSV 
vector per se is functional in pigs. Although several 
vector vaccines failed to induce a protective immune 
response, immunizations essentially primed the 
immune system to a challenge infection [41, 42]. These 
reports and the present study altogether suggest that 
the PRRSV envelope proteins are expressed in a way to 
hide partially from the immune system. Whether this 
immune evasion strategy is due solely to glycan shield-
ing [68] or to a particular intracellular topology remains 
to be investigated. Future efforts in vectored vaccine 
development should consider these aspects to enhance 
the immunogenicity of the PRRSV antigens.
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